---
title: Efficacy of Sacral Erector Spinae Plane Block (SESPB) on Postoperative Pain and Catheter-related Bladder Discomfort
nct_id: NCT06127394
overall_status: COMPLETED
phase: NA
sponsor: Giresun University
study_type: INTERVENTIONAL
primary_condition: Pain, Postoperative
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06127394.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06127394"
ct_last_update_post_date: 2024-05-17
last_seen_at: "2026-05-12T07:08:02.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy of Sacral Erector Spinae Plane Block (SESPB) on Postoperative Pain and Catheter-related Bladder Discomfort

**Official Title:** Comparison of the Efficacy of Sacral Erector Spinae Plane Block (SESPB) and Pudendal Block on Postoperative Pain and Catheter-related Bladder Discomfort (CRBD) in Patients Undergoing Trans-urethral Resection of the Prostate (TUR-P).

**NCT ID:** [NCT06127394](https://clinicaltrials.gov/study/NCT06127394)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 54
- **Lead Sponsor:** Giresun University
- **Conditions:** Pain, Postoperative
- **Start Date:** 2023-11-12
- **Completion Date:** 2023-12-15
- **CT.gov Last Update:** 2024-05-17

## Brief Summary

The goal of this clinical trial is to evaluate the catheter related bladder discomfort in patients who will undergoing TUR-P operation. The main questions it aims to answer are:

* Is sacral ESPB effective on the pudendal nerve dermatome?
* Is sacral ESPB as useful as pudendal block on CRBD? Participants will be divided into two groups and the first group will receive sacral espb after TUR-p operation and the second group will receive pudendal block. Investigators will be present for 24 hours

  * catheter related bladder discomfort
  * post-operative pain,
  * additional analgesic needs will be questioned and the difference between the two groups will be evaluated.

## Detailed Description

This is a prospective,randomised,double-blind, single-centre,study aiming to compare the effectiveness of US guided bilateral sacral ESPB and US guided bilateral pudendal block on CRBD and pain after TUR-P. 54 patients will be included in the study and divided into two groups. All patients will be standardly monitored and will receive general anaesthesia. At the end of the cases, sacral ESPB will be applied to the first group and pudendal block to the second group, and the patients and the data questioner physician will be blinded to the study.

Primary and secondary outcomes will be questioned for 24 hours and statistics will be made according to the result.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

\- American Society of Anesthesiologist (ASA) Physical status 1-3

Exclusion Criteria:

* American Society of Anesthesiologist (ASA) Physical status 4-5
* Refused to participate in the study
* Known allergy to local anaesthetic
* Where regional anaesthesia is contraindicated
* With known neurological, haematological or muscular disease
* Patients with infection or anatomical changes in the lumbo-sacral region
```

## Arms

- **espb group** (EXPERIMENTAL) — Block will be performed with median technique at the level of sacral 2nd vertebrae.
- **pudendal group** (ACTIVE_COMPARATOR) — Bilateral transperineal block will be performed

## Interventions

- **Sacral ESP Block** (PROCEDURE) — Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
- **Pudendal Block** (PROCEDURE) — Bilateral pudendal block, 10 ml %0,25 bupivacaine

## Primary Outcomes

- **Catheter related bladder discomfort, 0:no discomfort 4:worst discomfort** _(time frame: baseline ,and 24 hours)_ — It was evaluated with a 4-point scoring system developed and first used by Agarwall et al. . No symptoms: 0, Mild: mild discomfort that can be tolerated, Moderate: discomfort is present but not accompanied by behavioural reactions, Severe: discomfort is very severe and accompanied by body movements indicating that the patient cannot bear it.

## Secondary Outcomes

- **Numerical Rating Scale,0 :no pain 10:worst pain** _(time frame: baseline, and 24 hours)_

## Locations (1)

- Giresun Research and Training Hospital, Merkez, Giresun, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.giresun research and training hospital|merkez|giresun|turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06127394.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06127394*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*